renalytix.com (RNLX): Net earnings per share (EPS TTM)

RNLX (renalytix.com) - company brandmark

Renalytix Plc (RNLX) revenues are based on the implementation of AI tests in nephrology and the expansion of insurance coverage. The company's net income per share over 12 months clearly confirms the dynamics of financial flows, where -0.62 becomes the new value of the indicator. Patents and FDA approval create a defensive barrier, although high scientific competition in CKD diagnostics forces the company to constantly optimize the cost of its solutions.

RNLX renalytix.com Earnings per share for the last 12 months (07/04/2022 - 10/19/2024)

Analytical breakdowns and data insights for company Renalytix Plc (RNLX)

- stock price and consensus target price:
- stock exchange capitalization data:
General company analysis:Renalytix, plc (RNLX)
Flagship merchandise of Renalytix, plc

Investors must weigh the asset's current yield against its financial stability risks. This metric reflects the annual net profit per share, excluding the impact of share issuance. By analyzing the TTM fundamental earnings per share trend, one can assess the real efficiency of the business. For Renalytix Plc (RNLX), this trend is critical due to supply chain vulnerabilities and regulatory barriers in biopharmaceuticals. The upward trajectory confirms the company's ability to overcome geopolitical complexities.